We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aerie Pharmaceuticals Inc | NASDAQ:AERI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 15.25 | 15.24 | 14.79 | 0 | 01:00:00 |
|
|
|
|
|
Delaware
|
|
001-36152
|
|
20-3109565
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Shares of common stock, par value $0.001 per share
|
|
AERI
|
|
Nasdaq Global Market
|
|
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
Proposal 1:
|
Election of Directors.
|
Nominee
|
|
Votes For
|
|
Votes Withheld
|
|
Broker Non-Votes
|
Gerald D. Cagle, Ph.D.
|
|
36,779,516
|
|
1,129,618
|
|
3,761,061
|
|
|
|
|
|
|
|
Richard Croarkin
|
|
37,384,678
|
|
524,456
|
|
3,761,061
|
Proposal 2:
|
Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.
|
Votes For
|
|
Votes Against
|
|
Votes Abstained
|
|
Broker Non-Votes
|
41,524,701
|
|
136,654
|
|
8,840
|
|
—
|
Proposal 3:
|
To approve, by a non-binding vote, the compensation of the Company's named executive officers (“say-on-pay”).
|
Votes For
|
|
Votes Against
|
|
Votes Abstained
|
|
Broker Non-Votes
|
36,571,147
|
|
1,317,298
|
|
20,689
|
|
3,761,061
|
|
|
|
|
|
|
|
|
|
|
|
AERIE PHARMACEUTICALS, INC.
|
||
|
|
|
|
|||
Date: May 23, 2019
|
|
|
|
By:
|
|
/s/ Richard J. Rubino
|
|
|
|
|
|
|
Richard J. Rubino
|
|
|
|
|
|
|
Chief Financial Officer
|
1 Year Aerie Pharmaceuticals Chart |
1 Month Aerie Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions